Drug intelligence / Profile preview

DA-002

Development stage: Phase 3
Lead developer: Jupiter Wellness
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
Administration: Topical

Overview

DA-002 is a topical pharmaceutical agent under investigation for the treatment of hair loss, specifically androgenetic alopecia and pattern baldness in both males and females. It acts as an alpha 1 agonist, with its ingredients having demonstrated hair growth effects in vitro. The drug is being evaluated for efficacy and safety compared to topical minoxidil. Mechanistically, it appears to target the integrin subunit alpha 1 (CD49a), functioning as an agonist at this site[1][2][3]. Clinical trials are ongoing to assess its potential benefit in promoting hair regrowth.

Targets

ITGA1 (Integrin Subunit Alpha 1)

Beyond the preview

Go deeper on DA-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-002.

Explore the full profile